Stock Events

Stock Events

Kazia Therapeutics Limited 

$7.34
35
+$0.16+2.23% Thursday 20:00

Statistics

Day High
7.45
Day Low
7.09
52W High
17.4
52W Low
2.86
Volume
28,427
Avg. Volume
200,680
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28FebExpected
Q1 2021
Q2 2021
Q2 2021
Q3 2021
Q4 2021
Q4 2021
Q4 2023
-0.01
-0
-0
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-48,550.01%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
55,244.28Revenue
-26.82MNet Income

Analyst Ratings

$18.00Average Price Target
The highest estimate is 18.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KZIA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, competing with Kazia in the cancer metabolism space.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation works on small molecule drugs for oncology, putting it in direct competition with Kazia's therapeutic development.
Exelixis
EXEL
Mkt Cap10.41B
Exelixis, Inc. is involved in developing and commercializing new medicines for difficult-to-treat cancers, making it a competitor in the oncology market.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma specializes in the development of targeted small molecule drugs to treat cancer, directly competing with Kazia's focus.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of therapeutic areas including those targeted by Kazia.

About

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Show more...
CEO
Dr. John Edwin Friend II, M.D.
Employees
9
Country
US
ISIN
US48669G3039

Listings

XNAS
US
KZIA
BOATS
BOATS
KZIA.BOATS

0 Comments

Share your thoughts

FAQ

What is Kazia Therapeutics Limited stock price today?▼
The current price of KZIA is $7.34 USD — it has increased by +2.23% in the past 24 hours. Watch Kazia Therapeutics Limited stock price performance more closely on the chart.
What is Kazia Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kazia Therapeutics Limited stocks are traded under the ticker KZIA.
Is Kazia Therapeutics Limited stock price growing?▼
KZIA stock has risen by +2.51% compared to the previous week, the month change is a -16.4% fall, over the last year Kazia Therapeutics Limited has showed a +932.35% increase.
What is Kazia Therapeutics Limited revenue for the last year?▼
Kazia Therapeutics Limited revenue for the last year amounts to 55,244.28 USD.
What is Kazia Therapeutics Limited net income for the last year?▼
KZIA net income for the last year is -26.82M USD.
How many employees does Kazia Therapeutics Limited have?▼
As of April 04, 2026, the company has 9 employees.
In which sector is Kazia Therapeutics Limited located?▼
Kazia Therapeutics Limited operates in the Health Care sector.
When did Kazia Therapeutics Limited complete a stock split?▼
The last stock split for Kazia Therapeutics Limited was on April 17, 2025 with a ratio of 1:5.
Where is Kazia Therapeutics Limited headquartered?▼
Kazia Therapeutics Limited is headquartered in Sydney, US.